Advertisement PBR Staff Writer, Author at Pharmaceutical Business review - Page 3428 of 4440
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
 

All articles by  

Salix files NDA for ulcer drug

This application is based upon results from two large, multicenter, six-month, double-blind, randomized, placebo-controlled studies. These studies demonstrated a statistically significantly greater proportion of ulcerative colitis patients dosed

Cephalon submits NDA for lymphoma drug

The Treanda new drug application (NDA) for relapsed indolent non-Hodgkin’s lymphoma (NHL) is supported by three studies in patients with NHL, including one in combination with rituximab. In

Cyclacel initiates Phase II leukemia trial

The primary objective of this study is to evaluate the 1-year survival rate of three dosing schedules of sapacitabine in elderly patients with previously untreated or first relapsed

PRWT acquires chemical plant from Merck

Cherokee has also entered into a five-year supply agreement with Merck for an estimated value of $100-200 million annually. The Cherokee plant is a active pharmaceutical ingredient manufacturing